美国 · SEC FORM 4
uniQure N.V.
QURE · Nasdaq · CIK 0001590560 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
60 同一窗口内观察到的 Form 4 交易行
38 sales · 22 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 5 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot.—
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 8,715,837
- 上期报告
- 9,920,512
- 日均成交量
- 4,488,701
- 回补天数
- 1.9
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
本地 Form 4 历史中没有合资格的代码 P 股票买入。
Form 4 申报证据
90 transaction lines in the latest 365-day window; 465 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | Kapusta Matthew C | 卖出 (S) | Ordinary Shares | 21,082 | USD 45.16 | USD 952,051 | SEC 申报 ↗ |
| 2026-07-02 | Kapusta Matthew C | 期权行权/转换 (M) | Ordinary Shares | 21,082 | USD 19.39 | USD 408,780 | SEC 申报 ↗ |
| 2026-06-30 | Kaye Jack | 卖出 (S) | Ordinary Shares | 21,167 | USD 46.44 | USD 983,030 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | Kapusta Matthew C | 卖出 (S) | Ordinary Shares | 21,082 | USD 45.16 | USD 952,051 | SEC 申报 ↗ |
| 2026-07-02 | Kapusta Matthew C | 期权行权/转换 (M) | Ordinary Shares | 21,082 | USD 19.39 | USD 408,780 | SEC 申报 ↗ |
| 2026-06-30 | Kaye Jack | 卖出 (S) | Ordinary Shares | 21,167 | USD 46.44 | USD 983,030 | SEC 申报 ↗ |
| 2026-06-30 | Kaye Jack | 期权行权/转换 (M) | Ordinary Shares | 21,167 | USD 23.44 | USD 496,230 | SEC 申报 ↗ |
| 2026-06-30 | Abi-Saab Walid | 卖出 (S) | Ordinary Shares | 30,000 | USD 46.42 | USD 1,392,600 | SEC 申报 ↗ |
| 2026-06-30 | Abi-Saab Walid | 期权行权/转换 (M) | Ordinary Shares | 10,000 | USD 5.59 | USD 55,900 | SEC 申报 ↗ |
| 2026-06-26 | Abi-Saab Walid | 卖出 (S) | Ordinary Shares | 1,434 | USD 46.86 | USD 67,197 | SEC 申报 ↗ |
| 2026-06-25 | Kapusta Matthew C | 卖出 (S) | Ordinary Shares | 28,716 | USD 50.02 | USD 1,436,374 | SEC 申报 ↗ |
| 2026-06-25 | Kapusta Matthew C | 期权行权/转换 (M) | Ordinary Shares | 28,716 | USD 31.71 | USD 910,584 | SEC 申报 ↗ |
| 2026-06-24 | Kapusta Matthew C | 卖出 (S) | Ordinary Shares | 6,696 | USD 50.00 | USD 334,800 | SEC 申报 ↗ |
| 2026-06-24 | Kapusta Matthew C | 期权行权/转换 (M) | Ordinary Shares | 4,128 | USD 31.71 | USD 130,899 | SEC 申报 ↗ |
| 2026-06-18 | Kapusta Matthew C | 卖出 (S) | Ordinary Shares | 41,671 | USD 50.00 | USD 2,083,550 | SEC 申报 ↗ |
| 2026-06-18 | Kapusta Matthew C | 期权行权/转换 (M) | Ordinary Shares | 4,656 | USD 31.71 | USD 147,642 | SEC 申报 ↗ |
| 2026-06-17 | Kaye Jack | 卖出 (S) | Ordinary Shares | 5,295 | USD 42.57 | USD 225,408 | SEC 申报 ↗ |
| 2026-06-17 | Kaye Jack | 期权行权/转换 (M) | Ordinary Shares | 5,295 | USD 31.71 | USD 167,904 | SEC 申报 ↗ |
| 2026-06-17 | Kapusta Matthew C | 卖出 (S) | Ordinary Shares | 164,429 | USD 44.32 | USD 7,288,062 | SEC 申报 ↗ |
| 2026-06-17 | Kapusta Matthew C | 期权行权/转换 (M) | Ordinary Shares | 62,581 | USD 19.39 | USD 1,213,446 | SEC 申报 ↗ |
| 2026-06-17 | Balachandran Madhavan | 卖出 (S) | Ordinary Shares | 11,685 | USD 45.06 | USD 526,485 | SEC 申报 ↗ |
| 2026-06-17 | Balachandran Madhavan | 期权行权/转换 (M) | Ordinary Shares | 11,685 | USD 24.97 | USD 291,807 | SEC 申报 ↗ |
| 2026-06-15 | Potts Jeannette | 卖出 (S) | Ordinary Shares | 5,237 | USD 27.67 | USD 144,908 | SEC 申报 ↗ |
| 2026-06-15 | Balachandran Madhavan | 卖出 (S) | Ordinary Shares | 10,000 | USD 27.85 | USD 278,500 | SEC 申报 ↗ |
| 2026-06-15 | Balachandran Madhavan | 期权行权/转换 (M) | Ordinary Shares | 10,000 | USD 8.49 | USD 84,900 | SEC 申报 ↗ |
| 2026-06-11 | Springhorn Jeremy P. | 卖出 (S) | Ordinary Shares | 1,993 | USD 27.06 | USD 53,931 | SEC 申报 ↗ |
| 2026-06-11 | POST LEONARD E | 卖出 (S) | Ordinary Shares | 1,993 | USD 27.06 | USD 53,931 | SEC 申报 ↗ |
| 2026-06-11 | O'Keefe Kylie | 卖出 (S) | Ordinary Shares | 15,936 | USD 27.06 | USD 431,228 | SEC 申报 ↗ |
| 2026-06-11 | Meek David D. | 卖出 (S) | Ordinary Shares | 1,993 | USD 27.06 | USD 53,931 | SEC 申报 ↗ |
| 2026-06-11 | Kaye Jack | 卖出 (S) | Ordinary Shares | 1,993 | USD 27.06 | USD 53,931 | SEC 申报 ↗ |
| 2026-06-11 | Jacques Rachelle Suzanne | 卖出 (S) | Ordinary Shares | 1,993 | USD 27.06 | USD 53,931 | SEC 申报 ↗ |
| 2026-06-11 | Gut Robert | 卖出 (S) | Ordinary Shares | 2,726 | USD 27.06 | USD 73,766 | SEC 申报 ↗ |
| 2026-06-11 | Balachandran Madhavan | 卖出 (S) | Ordinary Shares | 1,993 | USD 27.06 | USD 53,931 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | QURE |
| CIK | 0001590560 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 465 transaction lines from 2020-01-07 to 2026-07-02 0 P purchase lines · 294 S sale lines · 171 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.